DBV Technologies, a late-stage biopharmaceutical company, will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit. The event will be held on February 11 and 12, 2026 in New York. Daniel Tassé, CEO of the company, will host an informal discussion on February 12 at 2:30 p.m. ET. This exchange will be broadcast live and available for 90 days on the DBV Technologies website.
Based in Châtillon, France, DBV Technologies is dedicated to developing treatments for food allergies using its VIASKIN® patch technology. This non-invasive method allows allergens to be introduced into the immune system through the skin. The company aims to meet significant unmet medical needs, particularly among young children with peanut allergies.
R. P.
date: 2026-02-10 01:45:00